methyl 1-butyl-1H-indazole-3-carboxylate | 173600-01-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: methyl 1-butyl-1H-indazole-3-carboxylate
• 英文别名: Methyl 1-butylindazole-3-carboxylate
• CAS: 173600-01-6
• 化学式: C₁₃H₁₆N₂O₂
• 分子量: 232.282
• InChiKey: GTANQMARPIGLBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 1-butyl-1H-indazole-3-carboxylate 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 生成 (S)-N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-butyl-1H-indazole-3-carboxamide
  参考文献：
  名称：

  缬氨酸、叔亮氨酸和苯丙氨酸氨基酸衍生的与 ADB-BUTINACA、APP-BUTINACA 和 ADB-P7AICA 相关的合成大麻素受体激动剂的构效关系

  摘要：

  合成大麻素受体激动剂 (SCRA) 仍然是全球最流行的新型精神活性物质 (NPS) 类别之一，在首次检测时，这些例子的特征通常很差。我们合成了与最近检测到的药物 ADB-BUTINACA、APP-BUTINACA 和 ADB-P7AICA 相关的氨基酸衍生的吲哚-、吲唑-和 7-azaindole-3-甲酰胺的系统文库，并对这些配体进行了体外结合的表征和对大麻素受体亚型 1 和 2（CB 1和 CB 2）的激动剂活性，以及​​体内大麻素活性。所有化合物都对 CB 1显示出高亲和力（K i 0.299–538 nM），大多数对 CB 2（K i = 0.912–2190 nM)，并且在基于荧光的膜电位测定和 βarr2 募集测定 (NanoBiT®) 中大部分用作 CB 1和 CB 2的高效激动剂，其中一些化合物是 NanoBiT® 中的部分激动剂化验。确定了 CB 1 /CB 2结合和 CB

  DOI：

  10.1039/d1md00242b
• 作为产物：
  描述：

  正溴丁烷 、 吲哚-3-甲酸甲酯 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 49.0h， 生成 methyl 1-butyl-1H-indazole-3-carboxylate
  参考文献：
  名称：

  枯基羧酰胺合成大麻新精神活性物质（NPS）CUMYL-BICA，CUMYL-PICA，CUMYL-5F-PICA，CUMYL-5F-PINACA的药理作用

  摘要：

  合成大麻素（SC）是新型精神活性物质（NPS）的最大类别，并且越来越多地与严重的不良反应联系在一起。SC NPS的大多数是1，3-二取代的吲哚和吲唑，在1和3位具有多种亚基。最近，执法机构和急诊部门发现了枯基衍生的吲哚和吲唑-3-羧酰胺。在本文中，我们描述了SCs CUMYL-BICA，CUMYL-PICA，CUMYL-5F-PICA，CUMYL-PINACA，CUMYL-5F-PINACA及其相关类似物的合成，表征和药理作用。所有枯基衍生的SC在CB 1（EC 50 = 0.43–12.3 nM）和CB 2（EC 50= 11.3–122 nM）受体在膜电位的荧光测定中，具有CB 1活化的选择性（是CB 2的3.1–53倍）。使用生物遥测法在大鼠中评估了CUMYL-PICA和CUMYL-5F-PICA，并以1 mg / kg的剂量诱发了体温过低和心动过缓。通过用CB 1而不是CB 2拮抗

  DOI：

  10.1021/acschemneuro.7b00267

文献信息

• Development of Potent Serotonin-3 (5-HT3) Receptor Antagonists. II. Structure-Activity Relationships of N-(1-Benzyl-4-methylhexahydro-lH-1,4-diazepin-6-yl)carboxamides.
  作者：Hiroshi HARADA、Toshiya MORIE、Yoshimi HIROKAWA、Hideo TERAUCHI、Iwao FUJIWARA、Naoyuki YOSHIDA、Shiro KATO

  DOI：10.1248/cpb.43.1912

  日期：——

  reflex in rats are described. Heteroaromatic rings such as pyrrole, thiophene, furan, pyridine, pyridazine, 1,2-benzisoxazole, indole, quinoline, and isoquinoline rings showed weak 5-HT3 receptor antagonistic activity. Within this series, use of the 1H-indazole ring as an aromatic moiety led to a substantial increase of the activity; the 1H-indazolylcarboxamides 54, 57, 97, and 102 showed potent 5-HT3

  我们对4-氨基-5-氯-2-乙氧基苯甲酰胺的研究导致发现N-（1,4-二甲基六氢-1H-1,4-二氮杂-6-6基）苯甲酰胺9和1-苄基-4 -甲基六氢-1H-1,4-二氮杂analogue类似物10是有效的血清素3（5-HT3）受体拮抗剂。描述了结构和活性关系（SAR）研究9和10的芳香核对大鼠von Bezold-Jarisch反射的抑制作用。杂芳族环，如吡咯，噻吩，呋喃，吡啶，哒嗪，1,2-苯并恶唑环，吲哚，喹啉和异喹啉环显示弱的5-HT3受体拮抗活性。在这个系列中，使用1H-吲唑环作为芳族部分会导致活性的大幅提高。1H-吲唑基羧酰胺54、57、97和102显示出有效的5-HT3受体拮抗活性。
• Synthesis and <i>in Vitro</i> Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA
  作者：Annelies Cannaert、Eric Sparkes、Edward Pike、Jia Lin Luo、Ada Fang、Richard C. Kevin、Ross Ellison、Roy Gerona、Samuel D. Banister、Christophe P. Stove

  DOI：10.1021/acschemneuro.0c00644

  日期：2020.12.16

  Synthetic cannabinoid receptor agonists (SCRAs) are an evolving class of new psychoactive substances (NPS) with structurally diverse compounds emerging each year. Due to the rapid pace at which these drugs enter the market, there is often little or nil information regarding the pharmacology of these substances despite widespread human use. In this study, 12 recently emerged SCRAs (reported between 2018 and 2020) were synthesized, analytically characterized, and pharmacologically evaluated using a live cell-based nanoluciferase complementation reporter assay that monitors in vitro cannabinoid receptor type 1 (CB1) activation via its interaction with β-arrestin 2 (βarr2). All synthesized SCRAs acted as agonists of CB1, although differences in potency (EC50 = 2.33-5475 nM) and efficacy (Emax = 37-378%) were noted, and several structure-activity relationships were identified. SCRAs featuring indazole cores (EC50 = 2.33-159 nM) were generally of equal or greater potency than indole analogues (EC50 = 32.9-330 nM) or 7-azaindole derivatives (EC50 = 64.0-5475 nM). Interestingly, with the exception of APP-BINACA (Emax = 75.7%) and 5F-A-P7AICA (Emax = 37.4%), all SCRAs showed greater efficacy than the historical SCRA JWH-018 to which responses were normalized (Emax = 142-378%). The most potent CB1 agonists in the study were ADB-BINACA (EC50 = 6.36 nM), 4F-MDMB-BINACA (EC50 = 7.39 nM), and MDMB-4en-PINACA (EC50 = 2.33 nM). Notably, all of these SCRAs featured an indazole core as well as a "bulky" tert-butyl moiety in the pendant amino acid side chain. This study confirms that recently detected SCRAs 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA were all able to activate the CB1 receptor in vitro, albeit to different extents, and are potentially psychoactive in vivo. These results indicate that further evaluation of these widely used NPS is warranted to better understand the risks associated with human consumption of these drugs.
• Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues
  作者：Mitchell Longworth、Samuel D. Banister、Rochelle Boyd、Richard C. Kevin、Mark Connor、Iain S. McGregor、Michael Kassiou

  DOI：10.1021/acschemneuro.7b00267

  日期：2017.10.18

  3-disubstituted indoles and indazoles featuring a diversity of subunits at the 1- and 3-positions. Most recently, cumyl-derived indole- and indazole-3-carboxamides have been detected by law enforcement agencies and by emergency departments. Herein we describe the synthesis, characterization, and pharmacology of SCs CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-PINACA, CUMYL-5F-PINACA, and related analogues

  合成大麻素（SC）是新型精神活性物质（NPS）的最大类别，并且越来越多地与严重的不良反应联系在一起。SC NPS的大多数是1，3-二取代的吲哚和吲唑，在1和3位具有多种亚基。最近，执法机构和急诊部门发现了枯基衍生的吲哚和吲唑-3-羧酰胺。在本文中，我们描述了SCs CUMYL-BICA，CUMYL-PICA，CUMYL-5F-PICA，CUMYL-PINACA，CUMYL-5F-PINACA及其相关类似物的合成，表征和药理作用。所有枯基衍生的SC在CB 1（EC 50 = 0.43–12.3 nM）和CB 2（EC 50= 11.3–122 nM）受体在膜电位的荧光测定中，具有CB 1活化的选择性（是CB 2的3.1–53倍）。使用生物遥测法在大鼠中评估了CUMYL-PICA和CUMYL-5F-PICA，并以1 mg / kg的剂量诱发了体温过低和心动过缓。通过用CB 1而不是CB 2拮抗
• Structure–activity relationships of valine, <i>tert</i>-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA
  作者：Eric Sparkes、Elizabeth A. Cairns、Richard C. Kevin、Felcia Lai、Katharina Elisabeth Grafinger、Shuli Chen、Marie H. Deventer、Ross Ellison、Rochelle Boyd、Lewis J. Martin、Iain S. McGregor、Roy R. Gerona、David E. Hibbs、Volker Auwärter、Michelle Glass、Christophe Stove、Samuel D. Banister

  DOI：10.1039/d1md00242b

  日期：——

  Synthetic cannabinoid receptor agonists (SCRAs) remain one the most prevalent classes of new psychoactive substances (NPS) worldwide, and examples are generally poorly characterised at the time of first detection. We have synthesised a systematic library of amino acid-derived indole-, indazole-, and 7-azaindole-3-carboxamides related to recently detected drugs ADB-BUTINACA, APP-BUTINACA and ADB-P7AICA

  合成大麻素受体激动剂 (SCRA) 仍然是全球最流行的新型精神活性物质 (NPS) 类别之一，在首次检测时，这些例子的特征通常很差。我们合成了与最近检测到的药物 ADB-BUTINACA、APP-BUTINACA 和 ADB-P7AICA 相关的氨基酸衍生的吲哚-、吲唑-和 7-azaindole-3-甲酰胺的系统文库，并对这些配体进行了体外结合的表征和对大麻素受体亚型 1 和 2（CB 1和 CB 2）的激动剂活性，以及​​体内大麻素活性。所有化合物都对 CB 1显示出高亲和力（K i 0.299–538 nM），大多数对 CB 2（K i = 0.912–2190 nM)，并且在基于荧光的膜电位测定和 βarr2 募集测定 (NanoBiT®) 中大部分用作 CB 1和 CB 2的高效激动剂，其中一些化合物是 NanoBiT® 中的部分激动剂化验。确定了 CB 1 /CB 2结合和 CB